{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:13:30Z","timestamp":1792782810774,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Zhejiang Province Traditional Chinese Medicine Science and Technology Project","award":["2023ZL652"],"award-info":[{"award-number":["2023ZL652"]}]},{"name":"Science and Technology Planning Project of Medicine and Public Health in Zhejiang Province","award":["2023KY252"],"award-info":[{"award-number":["2023KY252"]}]},{"name":"Chongqing Municipal Education Commission Science and Technology Research Project","award":["KJQN202515107"],"award-info":[{"award-number":["KJQN202515107"]}],"id":[{"id":"https:\/\/ror.org\/031nm5713","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the National Natural Science Foundation of China","award":["82072349"],"award-info":[{"award-number":["82072349"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Chongqing","award":["CSTB2024NSCQ-MSX1146"],"award-info":[{"award-number":["CSTB2024NSCQ-MSX1146"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10096-026-05547-9","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:31:00Z","timestamp":1779337860000},"page":"2729-2737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In vitro and in vivo antibacterial activity of oral tebipenem in combination with novel \u03b2-lactamase inhibitors (avibactam, relebactam, vaborbactam) against KPC-producing Enterobacterales"],"prefix":"10.1007","volume":"45","author":[{"given":"Chunhong","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongyao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunfang","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqiang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"5547_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jinf.2018.02.007","volume":"76","author":"JA Ramos-Casta\u00f1eda","year":"2018","unstructured":"Ramos-Casta\u00f1eda JA, Ruano-Ravina A, Barbosa-Lorenzo R, Paillier-Gonzalez JE, Salda\u00f1a-Campos JC, Salinas DF et al (2018) Mortality due to KPC carbapenemase-producing Klebsiella pneumoniae infections: systematic review and meta-analysis: mortality due to KPC Klebsiella pneumoniae infections. J Infect 76:438\u2013448. https:\/\/doi.org\/10.1016\/j.jinf.2018.02.007","journal-title":"J Infect"},{"key":"5547_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11908-018-0617-x","volume":"20","author":"AM Porreca","year":"2018","unstructured":"Porreca AM, Sullivan KV, Gallagher JC (2018) The epidemiology, evolution, and treatment of KPC-producing organisms. Curr Infect Dis Rep 20:13. https:\/\/doi.org\/10.1007\/s11908-018-0617-x","journal-title":"Curr Infect Dis Rep"},{"key":"5547_CR3","doi-asserted-by":"publisher","first-page":"e02048","DOI":"10.1128\/AAC.02048-18","volume":"63","author":"WR Wilson","year":"2019","unstructured":"Wilson WR, Kline EG, Jones CE, Morder KT, Mettus RT, Doi Y et al (2019) Effects of KPC variant and porin genotype on the in vitro activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents Chemother 63:e02048\u2013e02018. https:\/\/doi.org\/10.1128\/AAC.02048-18","journal-title":"Antimicrob Agents Chemother"},{"key":"5547_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, Bonomo RA et al (2022) European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect 28:521\u2013547. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025","journal-title":"Clin Microbiol Infect"},{"key":"5547_CR5","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","volume":"72","author":"PD Tamma","year":"2021","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ (2021) Infectious Diseases Society of America guidance on the treatment of Extended-Spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat resistance (DTR-P. aeruginosa). Clin Infect Dis 72:e169\u2013e183. https:\/\/doi.org\/10.1093\/cid\/ciaa1478","journal-title":"Clin Infect Dis"},{"key":"5547_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/cid\/ciy492","volume":"68","author":"M Tumbarello","year":"2019","unstructured":"Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C et al (2019) Efficacy of Ceftazidime-Avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis 68:355\u2013364. https:\/\/doi.org\/10.1093\/cid\/ciy492","journal-title":"Clin Infect Dis"},{"key":"5547_CR7","doi-asserted-by":"publisher","first-page":"e00883","DOI":"10.1128\/AAC.00883-17","volume":"61","author":"RK Shields","year":"2017","unstructured":"Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV et al (2017) Ceftazidime-Avibactam is superior to other treatment regimens against Carbapenem-Resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 61:e00883\u2013e00817. https:\/\/doi.org\/10.1128\/AAC.00883-17","journal-title":"Antimicrob Agents Chemother"},{"key":"5547_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00008-23","volume":"36","author":"L Ding","year":"2023","unstructured":"Ding L, Shen S, Chen J, Tian Z, Shi Q, Han R et al (2023) Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. Clin Microbiol Rev 36:e0000823. https:\/\/doi.org\/10.1128\/cmr.00008-23","journal-title":"Clin Microbiol Rev"},{"key":"5547_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2361007","volume":"13","author":"Q Shi","year":"2024","unstructured":"Shi Q, Shen S, Tang C, Ding L, Guo Y, Yang Y et al (2024) Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent Klebsiella pneumoniae. Emerging Microbes & Infections 13:2361007. https:\/\/doi.org\/10.1080\/22221751.2024.2361007","journal-title":"Emerging Microbes & Infections"},{"key":"5547_CR10","doi-asserted-by":"publisher","first-page":"e02618","DOI":"10.1128\/AAC.02618-18","volume":"63","author":"SJR Arends","year":"2019","unstructured":"Arends SJR, Rhomberg PR, Cotroneo N, Rubio A, Flamm RK, Mendes RE (2019) Antimicrobial activity evaluation of tebipenem (SPR859), an orally available carbapenem, against a global set of Enterobacteriaceae isolates, including a challenge set of organisms. Antimicrob Agents Chemother 63:e02618\u2013e02618. https:\/\/doi.org\/10.1128\/AAC.02618-18","journal-title":"Antimicrob Agents Chemother"},{"key":"5547_CR11","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00687-24","volume":"68","author":"D Ono","year":"2024","unstructured":"Ono D, Cmolik A, Bethel CR, Ishii Y, Drusin SI, Moreno DM et al (2024) The interaction of the azetidine thiazole side chain with the active site loop (ASL) 3 drives the evolution of IMP metallo-\u03b2-lactamase against tebipenem. Antimicrob Agents Chemother 68:e0068724. https:\/\/doi.org\/10.1128\/aac.00687-24","journal-title":"Antimicrob Agents Chemother"},{"key":"5547_CR12","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa2105462","volume":"386","author":"PB Eckburg","year":"2022","unstructured":"Eckburg PB, Muir L, Critchley IA, Walpole S, Kwak H, Phelan A-M et al (2022) Oral tebipenem pivoxil hydrobromide in complicated urinary tract infection. N Engl J Med 386:1327\u20131338. https:\/\/doi.org\/10.1056\/NEJMoa2105462","journal-title":"N Engl J Med"},{"key":"5547_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02240-19","author":"N Cotroneo","year":"2020","unstructured":"Cotroneo N, Rubio A, Critchley IA, Pillar C, Pucci MJ (2020) In vitro and in vivo characterization of Tebipenem, an oral carbapenem. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.02240-19","journal-title":"Antimicrob Agents Chemother"},{"key":"5547_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02396-21","volume":"66","author":"Z Sun","year":"2022","unstructured":"Sun Z, Su L, Cotroneo N, Critchley I, Pucci M, Jain A et al (2022) Evaluation of tebipenem hydrolysis by \u03b2-lactamases prevalent in complicated urinary tract infections. Antimicrob Agents Chemother 66:e0239621. https:\/\/doi.org\/10.1128\/aac.02396-21","journal-title":"Antimicrob Agents Chemother"},{"key":"5547_CR15","doi-asserted-by":"publisher","first-page":"e00547","DOI":"10.1128\/aac.00547-23","volume":"67","author":"C Le Terrier","year":"2023","unstructured":"Le Terrier C, Nordmann P, Bouvier M, Poirel L (2023) Impact of acquired broad-spectrum \u03b2-lactamases on susceptibility to oral penems\/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam \u03b2-lactamase inhibitors in Escherichia coli. Antimicrob Agents Chemother 67:e00547\u2013e00523. https:\/\/doi.org\/10.1128\/aac.00547-23","journal-title":"Antimicrob Agents Chemother"},{"key":"5547_CR16","doi-asserted-by":"publisher","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","volume":"34","author":"D Yahav","year":"2020","unstructured":"Yahav D, Giske CG, Gr\u0101matniece A, Abodakpi H, Tam VH, Leibovici L (2020) New \u03b2-lactam-\u03b2-lactamase inhibitor combinations. Clin Microbiol Rev 34:e00115\u2013e00120. https:\/\/doi.org\/10.1128\/CMR.00115-20","journal-title":"Clin Microbiol Rev"},{"key":"5547_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","volume":"78","author":"GG Zhanel","year":"2018","unstructured":"Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M et al (2018) Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-\u03b2-lactamase inhibitor combinations. Drugs 78:65\u201398. https:\/\/doi.org\/10.1007\/s40265-017-0851-9","journal-title":"Drugs"},{"key":"5547_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac105","volume":"4","author":"A Ranasinghe","year":"2022","unstructured":"Ranasinghe A, Henderson A, Cottrell K, Tan CSE, Burnard D, Kato H et al (2022) Determining the in vitro susceptibility of tebipenem, an oral carbapenem, against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae isolated from bloodstream infections. JAC Antimicrob Resist 4:dlac105. https:\/\/doi.org\/10.1093\/jacamr\/dlac105","journal-title":"JAC Antimicrob Resist"},{"key":"5547_CR19","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1128\/JCM.43.8.4178-4182.2005","volume":"43","author":"L Diancourt","year":"2005","unstructured":"Diancourt L, Passet V, Verhoef J, Grimont PAD, Brisse S (2005) Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol 43:4178\u20134182. https:\/\/doi.org\/10.1128\/JCM.43.8.4178-4182.2005","journal-title":"J Clin Microbiol"},{"key":"5547_CR20","unstructured":"M26-A Methods for Determining Bactericidal Activity of Antimicrobia l Agents; Approved Guideline"},{"key":"5547_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/jac\/dkm136","volume":"60","author":"JY Song","year":"2007","unstructured":"Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ et al (2007) In vitro activities of carbapenem\/sulbactam combination, colistin, colistin\/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 60:317\u2013322. https:\/\/doi.org\/10.1093\/jac\/dkm136","journal-title":"J Antimicrob Chemother"},{"key":"5547_CR22","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","volume":"25","author":"H Sati","year":"2025","unstructured":"Sati H, Carrara E, Savoldi A, Hansen P, Garlasco J, Campagnaro E et al (2025) The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. Lancet Infect Dis 25:1033\u20131043. https:\/\/doi.org\/10.1016\/S1473-3099(25)00118-5","journal-title":"Lancet Infect Dis"},{"key":"5547_CR23","doi-asserted-by":"publisher","unstructured":"Lomovskaya O, Rubio-Aparicio D, Tsivkovski R, Loutit J, Dudley M. The ultrabroad-spectrum beta-lactamase inhibitor QPX7728 restores the potency of multiple oral beta-lactam antibiotics against beta-lactamase-producing strains of resistant enterobacterales. Antimicrob Agents Chemother 66:e02168\u2013e02121. https:\/\/doi.org\/10.1128\/aac.02168-21","DOI":"10.1128\/aac.02168-21"},{"key":"5547_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/14787210.2018.1496821","volume":"16","author":"A Jain","year":"2018","unstructured":"Jain A, Utley L, Parr TR, Zabawa T, Pucci MJ (2018) Tebipenem, the first oral carbapenem antibiotic. Expert Rev Anti Infect Ther 16:513\u2013522. https:\/\/doi.org\/10.1080\/14787210.2018.1496821","journal-title":"Expert Rev Anti Infect Ther"},{"key":"5547_CR25","doi-asserted-by":"publisher","first-page":"e02181","DOI":"10.1128\/AAC.02181-18","volume":"63","author":"E Lacasse","year":"2019","unstructured":"Lacasse E, Brouillette E, Larose A, Parr TR, Rubio A, Malouin F (2019) In vitro activity of tebipenem (SPR859) against penicillin-binding proteins of Gram-Negative and Gram-Positive bacteria. Antimicrob Agents Chemother 63:e02181\u2013e02118. https:\/\/doi.org\/10.1128\/AAC.02181-18","journal-title":"Antimicrob Agents Chemother"},{"key":"5547_CR26","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1128\/JB.181.13.3981-3993.1999","volume":"181","author":"SA Denome","year":"1999","unstructured":"Denome SA, Elf PK, Henderson TA, Nelson DE, Young KD (1999) Escherichia coli mutants lacking all possible combinations of eight penicillin binding proteins: viability, characteristics, and implications for peptidoglycan synthesis. J Bacteriol 181:3981\u20133993. https:\/\/doi.org\/10.1128\/JB.181.13.3981-3993.1999","journal-title":"J Bacteriol"},{"key":"5547_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1128\/AAC.11.1.161","volume":"11","author":"BG Spratt","year":"1977","unstructured":"Spratt BG (1977) Comparison of the binding properties of two 6 beta-amidinopenicillanic acid derivatives that differ in their physiological effects on Escherichia coli. Antimicrob Agents Chemother 11:161\u2013166. https:\/\/doi.org\/10.1128\/AAC.11.1.161","journal-title":"Antimicrob Agents Chemother"},{"key":"5547_CR28","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1080\/21505594.2017.1313372","volume":"9","author":"R Roy","year":"2018","unstructured":"Roy R, Tiwari M, Donelli G, Tiwari V (2018) Strategies for combating bacterial biofilms: a focus on anti-biofilm agents and their mechanisms of action. Virulence 9:522\u2013554. https:\/\/doi.org\/10.1080\/21505594.2017.1313372","journal-title":"Virulence"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05547-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05547-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05547-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:34:19Z","timestamp":1789994059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-026-05547-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5547"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05547-9","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the formation of this paper\u2019s important intellectual content and reviewed and approved the final text for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors had sought consent from the individual to publish the data in a journal article.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}